In the year of our Lord 2024, it is with great anticipation that Savara Inc. a clinical-stage biopharmaceutical company dedicated to the advancement of therapies for rare respiratory afflictions, has publicly announced the acceptance of an abstract for the esteemed poster presentation at the forthcoming European Respiratory Society (ERS) Congress, scheduled to take place in the splendid city of Vienna, Austria, from the 7th to the 11th of September.
The proclaimed
Comments